BioCryst Pharmaceuticals
BCRX
257 hedge funds and large institutions have $1.32B invested in BioCryst Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 80 increasing their positions, 74 reducing their positions, and 34 closing their positions.
96% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $6.43M
53% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 34
22% more capital invested
Capital invested by funds: $1.08B → $1.32B (+$238M)
7% more funds holding
Funds holding: 241 → 257 (+16)
8% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 74
0.82% less ownership
Funds ownership: 84.49% → 83.67% (-0.82%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$8.13M |
| 3 |
BlackRock
New York
|
+$7.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.87M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$6.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
-$15.3M |
| 2 |
CCM
Cutter Capital Management
New York
|
-$8.95M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$7.15M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$6.87M |
| 5 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$6.76M |
BCRX Hedge Fund Activity: Q3 2024 in Review
257 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2024, worth a combined $1.32B — up 22% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new BCRX positions and 34 closed out — a net gain of 18 holders — while 80 added to existing stakes and 74 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.7M. The largest seller was Caligan Partners, cutting an estimated $15.3M.
- 257 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2024, up from 241 in Q2 2024.
- Funds reported $1.32B of BioCryst Pharmaceuticals stock for Q3 2024, up 22% quarter-over-quarter.
- 52 funds opened new BioCryst Pharmaceuticals positions in Q3 2024 and 34 closed out, a net change of +18 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $11.7M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2024 was Caligan Partners, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2024.